Peptide Nasal Sprays: Intranasal Formats in Research — and What’s Actually Sold in Canada
Last reviewed: September 2026
Search for a peptide nasal spray in Canada and every result is a research supplier selling one: BPC-157 atomisers, KPV sprays, Semax and Selank blends, PT-141 in a 10 mL bottle. What none of those pages explain is what the format actually is, why the intranasal route has a research history for some peptides and not others, and what you give up — in stability, in verifiability, in a certificate of analysis that means something — when a peptide arrives already dissolved. This guide is the companion to our oral peptides guide and takes the same position: the format a research supplier chooses is a statement about what can be tested, and the lyophilised vial is the format the research standard requires. That is why Quantum supplies vials and does not sell sprays.
What a peptide nasal spray is (and isn’t)
A peptide nasal spray is a peptide dissolved in an aqueous carrier — usually sterile or bacteriostatic water, sometimes saline, sometimes with a preservative or a mucoadhesive agent — and filled into a metered-dose atomiser, typically 5 to 10 mL. Each actuation delivers a fixed volume of solution; the quantity of peptide in that volume depends on the concentration the seller chose when the bottle was filled. Functionally it is a pre-mixed, pre-diluted peptide solution in a spray bottle, and nothing more exotic than that.
A lyophilised vial is the same peptide with the water removed: freeze-dried into a stable powder, sealed under an inert atmosphere, and reconstituted in the laboratory to whatever concentration the protocol calls for, using bacteriostatic water supplied separately. The chemistry of the peptide is identical. What differs is when the stability clock starts. A peptide in solution is exposed to hydrolysis, oxidation, adsorption to the container wall and microbial growth from the moment it is dissolved; a lyophilised peptide is exposed to none of those until reconstitution. For a spray, dissolution happened at the seller’s bench, on a date the buyer does not know, in a carrier the buyer did not choose. The consequences of that for shelf life are covered in the peptide shelf-life guide.
Intranasal delivery in peptide research: what the literature describes
The intranasal route has a genuine research literature, and it is worth being precise about what that literature is. The nasal cavity is lined with a highly vascular mucosa, and in animal models substances applied to it can enter systemic circulation without passing through the gut or the liver’s first-pass metabolism — the main reason it is studied at all for molecules that, like peptides, are destroyed by digestion. A second line of published work examines whether material applied to the olfactory region can reach the central nervous system along the olfactory and trigeminal nerve pathways, the so-called “nose-to-brain” hypothesis. Reviews of this literature describe it as active, mostly rodent-model, and highly compound-dependent: reported uptake is generally low, varies with molecular size, charge and formulation, and is sensitive to residence time on the mucosa, which is why many formulation studies add mucoadhesive or permeation-enhancing agents.
The peptides most associated with the route are the ones whose original research programmes used it. Semax and Selank, the two synthetic neuropeptides developed at the Institute of Molecular Genetics in Moscow, were studied intranasally from the outset, and the Russian-registered pharmaceutical products based on them are nasal drops — a matter of regulatory record in that jurisdiction, not a statement about any research material sold here. Oxytocin and vasopressin analogues have a large intranasal literature in neuroscience. For most of the peptides sold as sprays by Canadian research vendors, by contrast — BPC-157, TB-500, CJC-1295, KPV — the published preclinical work is overwhelmingly by injection or, in the case of BPC-157, by oral routes in rodents, and there is little or no peer-reviewed intranasal data at all. A spray format on a vendor’s shelf is not evidence that the route has been studied for that compound; it is evidence that the vendor owns a filling line.
Everything above is a description of animal-model and formulation-science findings. None of it is a claim that any research peptide is absorbed, reaches the brain, or does anything at all in a person, and no human pharmacokinetic comparison between intranasal and other routes exists for any compound in the research-supply market.
Nasal spray vs lyophilised vial: the format comparison
The question underneath “peptides nasal spray” is usually “why don’t all suppliers sell them?” The answer is that the two formats are not two versions of the same product; they differ on every axis a researcher should care about.
| Pre-mixed nasal spray | Lyophilised research vial | |
|---|---|---|
| What is in the container | Peptide + water/saline + (often) preservative, mucoadhesive or enhancer | Freeze-dried peptide only, sealed |
| Stability clock | Started at the seller’s fill date; solution degrades continuously, faster at room temperature and after opening | Starts at reconstitution, in the laboratory, on a known date |
| What a COA can certify | The lyophilised lot the seller started from — not the solution in the bottle after dilution, carrier and preservative were added | The exact material in the vial: batch-specific HPLC purity and MS identity |
| Concentration control | Fixed by the seller; fixed volume per actuation | Set by the researcher for the protocol |
| Independent re-testing | Difficult — carrier and additives complicate analysis, and the sample has aged in solution | Straightforward — dry material, standard HPLC/MS |
| Cost per milligram | Typically higher; the buyer pays for water, bottle and filling | Typically lower |
| Regulatory status in Canada | Unauthorised; research use only | Unauthorised as a drug; research use only |
The certificate-of-analysis row is the one that matters most. A per-batch COA is the only objective evidence a researcher has of what a supplier actually shipped, and it is issued on the lyophilised lot. Once that lot is dissolved, diluted to an undisclosed concentration, mixed with a carrier and left in a bottle for an unknown period, the certificate describes the starting material, not the product. Suppliers that sell sprays are not necessarily selling bad peptide; they are selling peptide that can no longer be checked. How to read a certificate is explained on the Certificate of Analysis hub.
Peptides commonly sold as nasal sprays by Canadian research suppliers
The Canadian research-supply market offers sprays of a handful of compounds. Below is what the published record says about each, and where the corresponding Quantum research page is. Quantum supplies each of the stocked compounds as a lyophilised vial only.
BPC-157 nasal spray
BPC-157 is the most widely sprayed peptide on Canadian vendor sites, and the one with the least intranasal justification in the literature. Its preclinical research history, almost all from one group in Zagreb using rodent models, is oral and parenteral; its distinguishing property is reported stability in gastric juice, which is a reason it appears in the oral literature and no reason at all to put it in a nasal atomiser. We are not aware of peer-reviewed intranasal BPC-157 pharmacokinetic work. Health Canada has not authorised any BPC-157 product in any format and named the compound in its April 2026 advisory on peptides sold online.
Semax and Selank
These are the two compounds for which the intranasal route is not a vendor invention but the original research design. Both are heptapeptide-class neuropeptides from the Moscow programme, both were characterised in rodent models by intranasal application, and both exist in Russia as registered nasal-drop pharmaceuticals — the only research-market peptides with that kind of regulatory history anywhere. That history is why “Semax nasal spray” and “Selank nasal spray” are the most common spray listings after BPC-157. It does not change their status in Canada, where neither is authorised, and it does not change what a Canadian research supplier can verify: Quantum supplies both as lyophilised vials with per-batch certificates, and the vial-versus-spray question for each is addressed on its own page.
PT-141
PT-141 (bremelanotide) is a melanocortin-receptor peptide with an intranasal chapter in its history: the early clinical-development programme for the pharmaceutical version tested a nasal formulation before the authorised product was ultimately developed as a subcutaneous injection. That is a fact about a drug-development programme in the United States, not about research materials. Sprays of PT-141 sold by Canadian vendors are pre-mixed research solutions with the same COA limitation as any other. Quantum’s supplied format is described on the product page.
KPV, TB-500 and CJC-1295
KPV — the C-terminal tripeptide of alpha-MSH — has become a common spray listing, studied in the literature in gut-inflammation models by oral and parenteral routes in mice. TB-500 (the thymosin beta-4 fragment) and CJC-1295 have no meaningful intranasal literature; both are 29- to 43-residue peptides whose preclinical work is parenteral. Quantum does not currently stock KPV, and does not supply a spray format of TB-500, CJC-1295 or any other compound.
Which format Quantum Peptides supplies, and why
Every peptide in the Quantum catalogue is supplied in one format: lyophilised powder in a sealed, batch-coded vial, tested per batch by an independent Canadian laboratory, with the report archived at a permanent URL on the lab results page. There are no nasal sprays, capsules, pens or pre-mixed solutions. The reason is the one the table above makes plain: a vial is the only format in which the material a researcher receives is the material the certificate describes. Reconstitution belongs in the laboratory, under the researcher’s own protocol, with bacteriostatic water supplied as a separate consumable. What a researcher does with a reconstituted solution in their own model is their protocol, not ours, and this page does not describe it. For how ordering works and what to check before buying from any Canadian supplier, see how to buy peptides in Canada or go straight to the research catalogue.
Regulatory status in Canada
No research peptide sold by any Canadian vendor — in spray, vial or any other format — is a Health-Canada-authorised drug or natural health product. None carries a DIN or NPN, and Health Canada’s April 2026 public advisory on peptides sold online applies regardless of the format on the label. A nasal spray is not a lower-regulated category; it is the same unauthorised molecule in a bottle with a pump. Research suppliers sell these materials for laboratory use only. The legal framework is set out on are peptides legal in Canada? and is not expanded here.
Frequently asked questions
What is a peptide nasal spray?
A peptide nasal spray is a research peptide dissolved in water or saline, often with a preservative or mucoadhesive additive, and filled into a metered atomiser that delivers a fixed volume per actuation. It is a pre-mixed solution prepared by the seller, as opposed to a lyophilised vial, which is freeze-dried peptide that the researcher reconstitutes in the laboratory.
How is intranasal peptide delivery described in the research literature?
Published animal-model and formulation studies describe the nasal mucosa as a route by which some molecules enter circulation without passing through the digestive tract, and investigate whether material applied to the olfactory region reaches the central nervous system along olfactory and trigeminal pathways. Reported uptake is generally low and strongly dependent on the peptide and the formulation. These are descriptions of laboratory findings, not claims about any product or any use in people.
Is a nasal spray or a lyophilised vial more stable?
The lyophilised vial. A peptide in solution degrades continuously through hydrolysis, oxidation and adsorption, faster at room temperature and after the container is opened; a freeze-dried peptide in a sealed vial is protected from all of those until reconstitution. A spray has been in solution since the seller filled it, on a date the buyer usually does not know.
Does a certificate of analysis cover a pre-mixed nasal spray?
Only indirectly. A COA is issued on a lyophilised lot and reports its purity and identity. Once that lot is dissolved, diluted to a concentration the buyer cannot verify, combined with a carrier and any additives, and stored in solution, the certificate describes the starting material rather than the product in the bottle. A lyophilised vial is the only format where the certificate and the contents are the same thing.
Which peptides are sold as nasal sprays in Canada?
Canadian research suppliers most commonly list BPC-157, Semax, Selank, PT-141, KPV, TB-500 and CJC-1295 in spray format. Of these, only Semax and Selank have an intranasal research history that predates the vendor market; the rest are sprayed because a filling line exists, not because the route has been studied for the compound.
Does Quantum Peptides sell peptide nasal sprays?
No. Quantum supplies research peptides as lyophilised powder in sealed, batch-coded vials with a per-batch third-party certificate of analysis, and sells bacteriostatic water separately as a laboratory consumable. There are no sprays, capsules, pens or pre-mixed solutions in the catalogue, and no plans to add them.
Are peptide nasal sprays approved by Health Canada?
No. No research peptide in any format is a Health-Canada-authorised drug or natural health product, and the format does not alter that status. Products sold by research suppliers are for laboratory use only. Questions about authorised medicines belong with a prescriber and pharmacist.
All products referenced on this page are supplied for laboratory research use only and are not for human or veterinary use. Literature statements summarise published preclinical and formulation-science findings and are not claims about any product. Regulatory statements reflect Health Canada’s Drug Product Database, Licensed Natural Health Products Database and public advisory as of September 2026. Page last reviewed September 2026.